PIPERACILLIN AND TAZOBACTAM

Post-LOE

piperacillin sodium and tazobactam sodium

ANDAPOWDER,FOR SOLUTIONINJECTION

Approved

Oct 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PIPERACILLIN AND TAZOBACTAM (piperacillin sodium and tazobactam sodium) is 12. Approved for older) for the treatment of appendicitis (complicated by rupture, abscess), peritonitis caused by beta-lactamase producing isolates of escherichia coli and 12 more indications. First approved in 2023.

Drug data last refreshed 6h ago

Mechanism of Action

12.1 Mechanism of Action Piperacillin and tazobactam is an antibacterial drug [see ] . 12.2 Pharmacodynamics The pharmacodynamic parameter for piperacillin and tazobactam that is most predictive of clinical and microbiological efficacy is time above MIC. 12.3 Pharmacokinetics The mean and…

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

PIPERACILLIN AND TAZOBACTAM

Mechanism of Action

Indications (15)